NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, has launched Hypoparathyroidism.com, an educational website for patients and caregivers dealing with this rare and complex disorder. Affecting an estimated 80,000 Americans, hypoparathyroidism is characterized by a number of physical and mental symptoms, including uncontrollable muscle spasms and cramps, tetany, seizures, fatigue, anxiety, and depression.
“The Hypoparathyroidism Association welcomes the launch of Hypoparathyroidism.com and believes it will be an important resource for our community of patients, as well as our caregivers,” said James Sanders, president, Hypoparathyroidism Association, Inc. “As a hypoparathyroidism patient, it is uplifting to see NPS’ recognition of our community needs and its dedication to providing accurate information about this rare disorder that is so often misunderstood.”
The website, Hypoparathyroidism.com, was developed in conjunction with experts in the field as a resource to connect patients with hypoparathyroidism, their families, and the healthcare professionals who treat them and provide information for those seeking knowledge about the endocrine condition. It offers first-hand patient experiences and numerous downloadable resources including guidance on how to talk to your doctor about the disorder and how to track calcium, vitamin D and phosphorus levels in foods. Using video and easy-to-understand text, the website provides an in-depth look at the causes and symptoms of the disorder. Hypoparathyroidism.com is also designed to meet the needs of healthcare professionals interested in knowing more about this rare disorder. It provides them with an overview of diagnosis and management, an animation explaining the mechanism of the disorder and links to peer-reviewed journal articles for in-depth exploration.
“Diagnosing the condition that they suffer from is often a critical component for those living with a rare disorder, especially for patients coping with symptoms that are uncommon and imply multiple organ systems,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “As such, we are proud to launch Hypoparathyroidism.com, as our contribution to offering patients and healthcare providers a dedicated educational resource that focuses on the unique needs of the hypoparathyroidism community.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV